Clinical trials: Patients With Diabetes.
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2
A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus.
- Trial name
- NCT00682097
- Testing
- RO4998452
- Where
- 3 sites in United States, Germany
- Volunteers
- 55 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 2
Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics
This study is conducted in Europe. Observational study evaluating the body weight progress during the treatment with insulin detemir (Levemir®) in Type 2 patients, previously treated with other basal insulins
- Trial name
- NCT00697450
- Testing
- insulin detemir
- Where
- Czechia
- Volunteers
- 206 people
- Sponsor
- Novo Nordisk A/S
Diabetes
Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus
The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes.
- Trial name
- NCT00057304
- Testing
- RO 205-2349
- Where
- 46 sites in United States, Bulgaria and 7 more
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes
This study is conducted in Europe, North America and Asia. The aim of this observational study is to evaluate the safety and effectiveness while using Levemir® once daily in combination with oral antidiabetic drugs in type 2…
- Trial name
- SOLVE™ (NCT00825643)
- Testing
- insulin detemir
- Where
- 9 sites in Canada, China and 7 more
- Volunteers
- 18,481 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.
- Trial name
- NCT01507311
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus
This randomized, multicenter, open-label, active-comparator, 2-arm, parallel-group, 6 month study with approximately 360 patients will compare the efficacy of two treatment regimens (Algorithm A versus Algorithm B) in…
- Trial name
- NCT00391209
- Testing
- simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder, intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
- Where
- 42 sites in United States, Argentina and 7 more
- Volunteers
- 379 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
Primary Objective: -To test the hypothesis that higher initial dose of basal insulin (0.3 U/kg) is non inferior to standard initial dose (0.2 U/kg) based on the percentage of patients with at least one episode of hypoglycemia…
- Trial name
- NCT02836704
- Testing
- INSULIN GLARGINE, metformin, acarbose
- Where
- China
- Volunteers
- 892 people
- Sponsor
- Sanofi
Diabetic Neuropathies, Diabetes Mellitus
Treatment of Peripheral Neuropathy in Patients With Diabetes
The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.
- Trial name
- NCT00044421
- Testing
- Ruboxistaurin mesylate
- Where
- 71 sites in United States, Australia and 13 more
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
To evaluate the efficacy of empagliflozin administered orally once daily in postprandial glucose and 24-hour glycaemic variability compared to placebo given for 4 weeks as mono-therapy in Japanese patients with type 2 diabetes…
- Trial name
- NCT01947855
- Testing
- Empagliflozin
- Where
- 2 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2
Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy
Primary objective of this study is to compare diabetes-related healthcare utilization and costs in patients initiating exenatide once weekly vs insulin glargine.
- Trial name
- NCT02843399
- Where
- United States
- Volunteers
- 15,498 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes
This study was not conducted in the United States. The purpose of this study was to assess the safety and effectiveness of a number of doses of vildagliptin, an unapproved drug, in the treatment of people with type 2 diabetes.
- Trial name
- NCT00238498
- Testing
- vildagliptin
- Volunteers
- 291 people
- Sponsor
- Novartis
Diabetic Ketoacidosis
REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis
A number of scientific papers have been published on the efficacy and safety of adding REAMBERIN® (meglumin sodium succinate), a 1.5% infusion solution, to standard therapy for patients with diabetic ketoacidosis (DKA), which…
- Trial name
- NCT06955416
- Testing
- Reamberin
- Where
- 3 sites in Russia
- Volunteers
- 312 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Painful Diabetic Neuropathy
A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)
Diabetic peripheral neuropathy (DPN) represents a diffuse symmetric and length-dependent injury to peripheral nerves that has major implications on quality of life (QOL), morbidity, and costs from a public health perspective.
- Trial name
- NCT01556152
- Testing
- GRC 17536 (Medium Dose), GRC 17536 (Low Dose)
- Where
- 2 sites in Germany, United Kingdom
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Diabetes Mellitus, Type 2
The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
This study will assess the effects of colesevelam, alone or in combination with sitagliptin, on glucose metabolism in subjects with T2DM inadequately controlled by diet and exercise
- Trial name
- NCT01092663
- Testing
- Colesevelam HCl, Sitagliptin
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- KineMed
Diabetic Nephropathy
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
This trial is randomized, placebo-controlled, double blind, double dummy, multi-centre trial. Screening period (4 week) Double blind treatment period (16 weeks)
- Trial name
- NCT01726816
- Testing
- Probucol 250mg/day, Probucol 500mg/day
- Where
- 16 sites in South Korea
- Volunteers
- 126 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Diabetic Neuropathy
An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy
The purpose of this study is to determine the efficacy and safety of Perampanel in patients with painful diabetic neuropathy.
- Trial name
- NCT00505284
- Testing
- E2007 (2 mg), E2007 (4 mg), E2007 (6 mg)
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- Eisai Inc.
Type 2 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
Primary Objective: To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at Month 6, Week 26) in participants with type 2 diabetes mellitus…
- Trial name
- EDITION III (NCT01676220)
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 217 sites in United States, Bulgaria and 14 more
- Volunteers
- 878 people
- Sponsor
- Sanofi
Diabetes
Interventional Clinical Trial Evaluating COVER PATCH CAPTEUR PROTECT Support Solutions for Continuous Glucose Monitoring Sensors in Patients With Diabetes
The aim of this clinical trial is to evaluate whether the COVER PATCH adhesive patch can improve the adhesion of continuous glucose monitors (CGMs).
- Trial name
- ICP-COVERPATCH (NCT07018180)
- Testing
- Use of COVER patchs for continuous glucose monitoring sensor
- Where
- 7 sites in France, Guadeloupe
- Volunteers
- 194 people
- Sponsor
- CAPTEUR PROTECT
Diabetic Foot Ulcer
Oral BBR-012 in the Treatment of Diabetic Foot Ulcers, Proof of Concept Study
The aim of this Clinical Proof of Principle study is to evaluate the effect of BBR-012 on the healing of complicated diabetic foot ulcers.
- Trial name
- BBR-012 (NCT01342497)
- Testing
- isoniazide
- Where
- 11 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Bridge BioResearch Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.